Trump Administration Narrowed GLOBE Drug Pricing Model
The exemption for manufacturers with separate pricing deals shifts compliance for drugmakers and hospitals.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Do you trust that government-negotiated drug pricing deals effectively lower costs for patients?
The Trump administration finalized a rule that exempts drugmakers with separate pricing agreements from the GLOBE Medicare drug pricing model, narrowing participation to four companies. This change significantly reduces the anticipated financial impact of the hospital-focused pricing program.
Why it matters
The exemption alters the competitive landscape for pharmaceutical companies and shifts cost-reduction expectations for federal Medicare programs. Regulators have moved away from broad participation, opting instead for a model built on individual bilateral agreements with manufacturers.
The GLOBE model is now limited to four manufacturers, a sharp contraction from original expectations. The administration estimates $440 million in Medicare Part B savings, well below the $11.9 billion projection initially associated with the program.
The players
The Trump Administration
The current federal executive branch responsible for national healthcare policy, rulemaking, and the negotiation of bilateral pricing agreements with the pharmaceutical sector.
Department of Health and Human Services
The cabinet-level executive agency that oversees federal health programs including Medicare and carries out the implementation of the GLOBE drug pricing model.
The details
Under the new rule, the Department of Health and Human Services waives GLOBE participation requirements for any manufacturer that has already negotiated a separate most favored nation pricing agreement with the White House. This mechanism allows firms with active, independent deals to bypass the standardized pricing constraints imposed on hospital-administered drugs. Consequently, the program now functions as a backstop for companies without existing, privately negotiated government contracts.
Timeline
2025: The administration began signing separate drug pricing agreements.
October 1, 2026: The finalized rule was officially published.
Market Landscape
The exemption marks a significant retreat from the original scope of the GLOBE Medicare drug pricing model, which was designed to standardize hospital drug costs. The strategy follows a broader trend of the administration favoring individualized pricing agreements over industry-wide regulatory mandates.
Operators in the pharmaceutical and hospital sectors should monitor whether their supply contracts fall under the four-manufacturer GLOBE mandate or a separate private agreement. Financial planning should account for the revised federal savings projections of $440 million rather than the prior $11.9 billion figure.
The takeaway
The move signals that the administration is prioritizing direct, company-specific negotiations to reach drug pricing goals. Business leaders should track the list of participants to determine if their drug procurement costs will be affected by the GLOBE model or independent price floors.
Further reading
For more on evolving regulatory policies, visit the Healthcare section.
Live Poll
Do you trust that government-negotiated drug pricing deals effectively lower costs for patients?
